Verified peer comparison

ABBV vs AMGN

AbbVie Inc. compared with Amgen Inc.. This page compares both source-verified company profiles and does not introduce an unverified price target.

ABBV

AbbVie Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

AMGN

Amgen Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

ABBV: Biotechnology

AMGN: Biotechnology

Upside lens

ABBV: Continued Skyrizi and Rinvoq adoption is expanding AbbVie's immunology portfolio and replacing revenue lost after Humira's U.S. exclusivity expiry. Growth across Vraylar, Botox Therapeutic, the migraine portfolio, and Vyalev broadens AbbVie's growth base beyond immunology. Regulatory submissions, approvals, and key clinical data readouts expected over the next year could add indications and reinforce the post-Humira portfolio transition.

AMGN: Broad volume growth across Repatha, EVENITY, rare-disease and oncology products can offset declines in mature brands. MariTide and other Phase 3 programs can create new growth franchises if clinical and regulatory milestones succeed. Expansion of UPLIZNA, IMDELLTRA and other newer medicines can diversify product growth.

Risk lens

ABBV: Humira revenue continues to contract after biosimilar entry, leaving execution on replacement growth products essential to the portfolio transition. Imbruvica declines are weighing on oncology, requiring growth from Venclexta, Elahere, and pipeline assets to offset the mature brand. U.S. drug-pricing policy, including the selection of Botox for Medicare negotiated prices beginning in 2028, could pressure future revenue and margins.

AMGN: Competition is accelerating declines in Prolia, XGEVA and other established products. Medicare price setting, 340B mix, payer pressure and global reforms can reduce net selling prices. Clinical failures can impair growth expectations while acquisition-related debt and commitments limit flexibility.